Switzerland: Johnson & Johnson to obtain rights to develop Numab’s NM26 for US$1.25bn
Numab Therapeutics, a clinical stage biotechnology company, is selling Yellow Jersey Therapeutics (YJT), a wholly-owned subsidiary of Numab, to US-based multinational Johnson & Johnson...
Sweden: Calliditas board accepts Asahi Kasei offer of SEK11.8bn
Japan-based Asahi Kasei Corp has offered to acquire the shares of Sweden-based Calliditas Therapeutics.
Asahi Kasei will offer to acquire all of the ordinary shares...
KSA: TVM Capital Healthcare closes Afiyah Fund at US$250m
TVM Capital Healthcare, an international healthcare expansion and growth capital investor, has closed the TVM Healthcare Afiyah Fund at approximately US$250m, its second pool of...
UK: Medical Properties Trusts completes £631m loan backed by UK portfolio
Medical Properties Trust (MPT), a US based hospital REIT, has completed a new £631m (US$800m) non-recourse, non-amortizing secured financing backed by certain properties in...
Italy: XGEN announces first fund with €160m in subscriptions
XGEN Venture – a newly formed Venture Capital firm – has announced its first fund, XGEN Venture Life Science Fund, with €160m (US$173m) in...
UK: Bicycle Therapeutics raises US$555m via PIPE
Nasdaq-listed Bicycle Therapeutics, a UK-headquartered pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, has...
Germany: Merck KGaA to acquire Mirus Bio for US$600m
Merck KGaA is to acquire Mirus Bio, a provider of transfection products for the biopharmaceutical and research industries, from Gamma Biosciences, a life sciences...
Italy: Gerresheimer to acquire Bormioli Pharma Group
Gerresheimer Glas, an indirect subsidiary of global partner to the pharma, biotech, and cosmetics industries Gerresheimer, is to acquire Blitz LuxCo, the holding company...
UK: New care home for Gravesend following land sale
Property adviser, Christie & Co, has announced the sale of a development site in Gravesend, Kent, which benefits from planning permission for a 75-bedroom...
Switzerland: SixPeaks Bio emerges from stealth with US$110m in fundinig
SixPeaks Bio has emerged from stealth with a pipeline of therapies for healthy weight loss and US$110m in funding. The company has secured US$30m...
Advertisement
